Celltrion, Stock Price +0.31% at This Time... Foreigners Net Buy 420,634 Shares in Last 5 Days
As of 2:30 PM on the 31st, Celltrion is trading at 324,500 KRW, up 0.31% from the previous day. The trading volume is 371,101 shares, which is 62.99% of the previous day's volume. Celltrion is known as a protein and biopharmaceutical manufacturing company.
On March 29, Minjeong Seon, a researcher at Hana Financial Investment, stated, "Rekkirona has received a usage recommendation opinion from the European EMA. With this, Rekkirona has become the third COVID-19 antibody treatment to receive conditional approval in Europe. Celltrion's Rekkirona is a single antibody treatment. Considering that Eli Lilly's COVID-19 single antibody treatment Bamlanivimab was supplied at $1,250 per dose in 2020, the price of Rekkirona is estimated to be similar." She set Celltrion's target price at 425,000 KRW.
Over the past five days, individual investors have net sold 400,321 shares of Celltrion, while foreigners and institutions have net bought 420,634 shares and 32,142 shares, respectively.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- [One Year of the Lee Jaemyung Administration] KFTC Uncovers Consecutive 20 Trillion Won Mega Cartels... Deflates Sugar and Ramen Prices
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
※Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an article automation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
